地诺单抗纳入医保没?
In 2009, (denosumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis, the treatment of bone destruction caused by bone metastasis of breast cancer, prostate cancer, and multiple myeloma, and the prevention of severe bone pain and skeletal-related events (SREs) caused by bone metastasis of malignant solid tumors, such as pathological fractures, spinal cord compression syndrome, etc.
In a study analysis, James et al. evaluated the effect of denosumab and zoledronic acid in the treatment of bone-related events of prostate cancer bone metastasis, showing that compared with zoledronic acid, denosumab can significantly reduce the risk of bone-related events. A large phase III clinical trial in the United States for patients with newly diagnosed multiple myeloma showed that compared with zoledronic acid, denosumab was not inferior in preventing skeletal-related events and could improve patient survival rate with significantly reduced nephrotoxicity.
The treatment effect of denosumab is remarkable. Is it included in the medical insurance in China?
It is reported that denosumab is currently on the market in China, but it has not yet been included in medical insurance. If patients want to buy cheap denosumab, they can choose denosumab available in Turkey. The specifications of Turkish denosumab are 125mg/1ml tube/box, and the price is equivalent to RMB 3,000.
If domestic patients want to purchase Turkish denosumab, they should choose regular drug purchase channels. There are currently many counterfeit Turkish drugs on the market. The use of counterfeit drugs for treatment not only poses a major hidden danger to the patient's life safety, but also has a low effective concentration of the drug in the counterfeit drugs, which may develop drug resistance and make it difficult to treat the disease even if it is taken with genuine drugs. Therefore, it is recommended that patients get their medicines directly from regular Turkish hospitals. In addition, you can also obtain genuine denosumab marketed in Turkey through domestic professional overseas medical service institutions.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)